(Young Investigator Award of the International Myeloma Society)
(ÚNKP-19-4-SE-83)
(NVKP_16-1-2016-0005)
Szakterületek:
Hematológia
Onkológia
Despite the introduction of novel agents, multiple myeloma remains incurable for most
patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2
inhibitor, had shown promising results in patients with translocation t(11;14), but
questions remain open about its optimal use. We have contacted all Hungarian haematology
centers for their experience treating t(11;14) myeloma patients with venetoclax. 58
patients were reported. 37 received venetoclax in the relapsed/refractory setting
with few or no other therapeutic options available. 21 patients started venetoclax
as salvage after failing to achieve satisfactory response to first line therapy. In
the relapsed/refractory setting objective response rate (ORR) was 94%, median progression-free
survival (PFS) 10.0 months and median overall survival (OS) 14.6 months. In reinduction
patients, ORR was 100%, median PFS and OS were not reached. Importantly, we found
no adverse effect of high risk features such as deletion 17p or renal failure, in
fact renal failure ameliorated in 42% of the cases, including three patients who became
dialysis independent. Our study also reports the highest number of plasma cell leukemia
cases successfully treated with venetoclax published in literature, with refractory
plasma cell leukemia patients achieving a median PFS of 10.0 and a median OS of 12.2
months.
